Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

China

As a participant in the lifesciences and healthcare industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market. With over 150 international specialists across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
11/07/2016
Ex­pect­a­tion of a Faster Growth of Health Food in Near...
China In­sight - Lifes­ci­ences
05/04/2016
New GCP of Med­ic­al Devices
China In­sight - Lifes­ci­ences
05/04/2016
China En­cour­ages In­nov­at­ive Drug by Modi­fy­ing Its Drug...
China In­sight - Lifes­ci­ences

Feed

Show only
15 Oct 19
High­lights on Ad­verse Event Fol­low­ing Im­mun­iz­a­tion...
16 Oct 19
High­lights on Ad­verse Event Fol­low­ing Im­mun­iz­a­tion Com­pens­a­tion Un­der...
On 29 June 2019, the Stand­ing Com­mit­tee of the Na­tion­al People’s Con­gress pro­mogu­lated the Law of People’s Re­pub­lic of China (the “PRC”) on Vac­cines Ad­min­is­tra­tion (the “Vac­cines Ad­min­is­tra­tion...
09 Oct 19
Re­vised Drug Ad­min­is­tra­tion Law
10 Oct 19
Re­vised Drug Ad­min­is­tra­tion Law
On 26 Au­gust 2019, the Stand­ing Com­mit­tee of the Na­tion­al People’s Con­gress of the People’s Re­pub­lic of China (the “PRC”) pro­mul­gated the re­vised PRC Drug Ad­min­is­tra­tion Law (the “Re­vised Drug...
25 Sep 19
CMS, China talks about the new reg­u­la­tions on PRC Drug...
03 Oct 19
In­ter­im meas­ures in Main­land Chinese courts in aid of Hong Kong-seated...
On 1 Oc­to­ber 2019, the Ar­range­ment Con­cern­ing Mu­tu­al As­sist­ance in Court-ordered In­ter­im Meas­ures in Aid of Ar­bit­ral Pro­ceed­ings (the “Ar­range­ment”), con­cluded between China’s Su­preme People’s...
09 Sep 19
Vac­cines Ad­min­is­tra­tion Law in China
19 Sep 19
China ex­pands cent­ral­ised drug pro­cure­ment scheme na­tion­wide
Fur­ther to the im­ple­ment­a­tion of its cent­ral­ised pro­cure­ment re­gime in 11 ma­jor cit­ies in Novem­ber 2018, China re­cently ex­pan­ded this re­gime to 29 provinces and four mu­ni­cip­al­it­ies across the coun­try...
16 Aug 19
High­lights on Re­cent Reg­u­la­tions on Cus­tom­ized Med­ic­al...
10 Sep 19
Vac­cines Ad­min­is­tra­tion Law in China
On 29 June 2019, the Stand­ing Com­mit­tee of the Na­tion­al People’s Con­gress of the People’s Re­pub­lic of China (the “PRC”) pro­mul­gated the PRC Vac­cines Ad­min­is­tra­tion Law (the “Vac­cines Ad­min­is­tra­tion...
09/08/2019
Ex­ten­sion of Pi­lot Re­gime of Med­ic­al Device Hold­er
29 Aug 19
China an­nounces ma­jor changes to its drug reg­u­lat­ory re­gime
Fol­low­ing years of dis­cus­sion and de­bate, the 12th Ses­sion of the Stand­ing Com­mit­tee of Chin­a's Na­tion­al People's Con­gress passed the Amend­ment of the Drug Ad­min­is­tra­tion Law of the People’s Re­pub­lic...